Drugs / FT538
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05700630 | Jul 2024 | HIV infectious disease, immunodeficiency disease | Masonic Cancer Center, University of Minnesota | Withdrawn | No outcome recorded |
| Phase 1 | NCT05708924 | Apr 2023 → Aug 2024 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 1 | NCT04714372 | Nov 2021 → Jan 2024 | acute myeloid leukemia, monocytic leukemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT05069935 | Oct 2021 → Aug 2023 | cancer | Fate Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT04614636 | Oct 2020 → Jul 2023 | acute myeloid leukemia, plasma cell myeloma | Fate Therapeutics | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT538 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04614636 ↗ |
| Action | Inhibit | “the knock-out of CD38 expression prevent anti-CD38 antibody-induced fratricide.” NCT05700630 ↗ |
| Modality | Cell therapy | “Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell” NCT04614636 ↗ |
| Route | Intravenous | “FT538 is administered as an IV infusion via gravity” NCT04714372 ↗ |
| Target | CD38 | “the knock-out of CD38 expression prevent anti-CD38 antibody-induced fratricide.” NCT05700630 ↗ |